(2022-04-20 | NDAQ:AZN) EVUSHELD (TM) significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results